NCT01091831已完成3 期
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus1 个研究点 分布在 1 个国家目标入组 389 人开始时间: 2009年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 389
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
This is a multicenter, randomized, open label study designed to compare the efficacy and safety of lenalidomide with low-dose alkylating agents versus high-dose melphalan followed by stem cell support in newly diagnosed symptomatic MM patients who are 65 years of age or younger.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
- •Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •Patient is 65 years old or younger at the time of signing the informed consent
- •Women of child-bearing potential must agree to use 2 methods of contraception: 1 effective (for example hormonal or tubal ligation) and 1 barrier (for example latex condom, diaphragm) for at least 4 weeks before starting the therapy, during the Treatment Period, and for 4 weeks after the last dose of lenalidomide
- •Male patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) during study drug therapy (including dose interruption) and for 4 weeks after discontinuation of lenalidomide therapy.
- •Negative serum beta-human chorionic gonadotropin ( beta-HCG) pregnancy test both 24 hours prior to beginning of therapy and then at 4 weeks intervals in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles during study treatment for subjects of childbearing potential
- •Patient was diagnosed with symptomatic multiple myeloma based on standard criteria (10), and has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, greater than 1 g/dL of IgG M-Protein and greater than 0.5 g/dL of IgA M-Protein) and, where applicable, urine light-chain excretion of >200 mg/24 hours; measurable plasmacytoma > 2 cm as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan); bone marrow plasma cells >10%.
- •Patient has a Karnofsky performance status ≥ 60%.
- •Patient has a life-expectancy > 6 months
- •Patient has HBV, HCV and HIV negative test.
- •Patients must have normal ECG and NYHA ≤ 2; an evaluation of ejection fraction by ECHO or MUGA is optional
- •Patients must normal chest X ray; an evaluation of pulmonary function studies on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) is optional.
- •Patient has the following laboratory values within 14 days before Baseline (day 1 of the Cycle 1):
- •Platelet count ≥ 75 x 109/L without transfusion support within 7 days before the test.
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without the use of growth factors.
- •Corrected serum calcium ≤ 14 mg/dL (3.5 mmol/L).
- •Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal (ULN).
- •Alanine transaminase (ALT): ≤ 2.5 x the ULN.
- •Total bilirubin: ≤ 1.5 x the ULN.
- •Calculated or measured creatinine clearance: ≥ 20 mL/minute
- •Patient has a baseline bone marrow sample available for cytogenetics, that will be processed and eventually centralized.
排除标准
- •Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid; < to the equivalent of dexamethasone 40 mg/day for 4 days).
- •Any serious medical condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he or she participates in this study or confounds the experimental ability to interpret data from the study.
- •Pregnant or lactating women. A serum β-hCG pregnancy test must be performed at the Screening visit, for female patients of child-bearing potential. If the test is positive, the patient must be excluded from the study. Confirmation that the patient is not pregnant must be established by a negative serum or urinary pregnancy test with the result obtained 1 day prior to the Baseline visit (or the day of the visit if results are available before drug delivery). A pregnancy test is not required for naturally post-menopausal women (who have not had menses at any time in the preceding 24 consecutive months) or surgically sterilised women (hysterectomy, bilateral ovariectomy, bilateral salpingectomy);
- •Prior history of malignancies, other than multiple myeloma, unless the subject has been free of the disease for ≥ 3 years. Exceptions include the following: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
- •Patients previously diagnosed as bearing deep venous thrombosis or arterial thromboembolic event within the latest 12 months.
研究组 & 干预措施
CRD
Active Comparator
Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
干预措施: Cyclophosphamide (Drug)
CRD
Active Comparator
Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
干预措施: Lenalidomide (Drug)
CRD
Active Comparator
Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
干预措施: Dexamethasone (Drug)
MEL200
Active Comparator
High dose Melphalan therapy (200 mg/m2) followed by stem cell support for 2 cycles every 4 months (for 1 cycle if at least VGPR was achieved after the 1st MEL200)
干预措施: Melphalan (Drug)
结局指标
主要结局
Progression free survival
时间窗: 5 years
次要结局
- Overall survival(5 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490
已完成
3 期
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerNon-Small Cell Lung CancerNCT03594747BeiGene360
撤回
3 期
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPDChronic Obstructive Pulmonary DiseaseCOPDNCT01393145Ache Laboratorios Farmaceuticos S.A.
进行中（未招募）
3 期
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic LeukemiaNCT04075292AstraZeneca155
已完成
3 期
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityType 2 DiabetesObesityNCT06184568Innovent Biologics (Suzhou) Co. Ltd.349